Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Raptor Pharmaceutical has signed a research collaboration agreement with a Stanford University professor relating to the use of NeuroTrans to deliver therapeutics across the blood-brain barrier.
Subscribe to our email newsletter
The agreement is between Raptor Pharmaceutical, a subsidiary of Raptor Pharmaceuticals Corp, and Dr William Mobley, professor of neurology and neurological sciences at the Stanford School of Medicine and director of the Neuroscience Institute at Stanford.
Dr Mobley’s lab will study the utility of the biotech company’s proprietary receptor-associated protein (RAP) vectors, collectively referred to as NeuroTrans, as potential transporters of intravenously administered therapeutics across the blood-brain barrier.
“We believe this work will lead to a deeper understanding of the biology of the blood-brain barrier, as well as the potential of RAP as a means of delivering protein therapeutics into the brain,” stated Dr Christopher Starr, Raptor Pharmaceutical’s CEO. “We believe this work may ultimately lead to potential treatments of a wide variety of neurodegenerative diseases.”